RHHBY Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of -- compared to Roche Holding AG's net margin of -106.6%. Roche Holding AG's return on equity of 23.8% beat CRISPR Therapeutics AG's return on equity of -18.65%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 20.97%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.92 which suggests that it could grow by 129.97%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.467, which suggesting that the stock is 53.264% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.877, suggesting its more volatile than the S&P 500 by 87.729%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.62%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. Roche Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$136M. Notably, Roche Holding AG's price-to-earnings ratio is 26.73x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.52x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Roche Holding AG's net margin of 21.68%. Roche Holding AG's return on equity of 23.8% beat Eli Lilly and's return on equity of 78.25%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 20.97%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Eli Lilly and has higher upside potential than Roche Holding AG, analysts believe Eli Lilly and is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.467, which suggesting that the stock is 53.264% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.62%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Roche Holding AG's net income of -- is lower than Eli Lilly and's net income of $2.8B. Notably, Roche Holding AG's price-to-earnings ratio is 26.73x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.52x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -- compared to Roche Holding AG's net margin of 37.18%. Roche Holding AG's return on equity of 23.8% beat Novo Nordisk AS's return on equity of 84.88%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 20.97%. On the other hand Novo Nordisk AS has an analysts' consensus of $91.52 which suggests that it could grow by 39.16%. Given that Novo Nordisk AS has higher upside potential than Roche Holding AG, analysts believe Novo Nordisk AS is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.467, which suggesting that the stock is 53.264% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.62%. Novo Nordisk AS offers a yield of 2.46% to investors and pays a quarterly dividend of $1.10 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Roche Holding AG's net income of -- is lower than Novo Nordisk AS's net income of $4.1B. Notably, Roche Holding AG's price-to-earnings ratio is 26.73x while Novo Nordisk AS's PE ratio is 19.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.52x versus 6.72x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 26.48%. Roche Holding AG's return on equity of 23.8% beat Novartis AG's return on equity of 30.96%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 20.97%. On the other hand Novartis AG has an analysts' consensus of $112.37 which suggests that it could grow by 3.38%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Roche Holding AG has a beta of 0.467, which suggesting that the stock is 53.264% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.726%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.62%. Novartis AG offers a yield of 3.67% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $3.6B. Notably, Roche Holding AG's price-to-earnings ratio is 26.73x while Novartis AG's PE ratio is 17.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.52x versus 4.12x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.